Akero Therapeutics reported Monday strong results from a nearly two-year, placebo-controlled study showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused by the liver disease known as MASH.
After 96 weeks, 39% of patients offered a 50-mg dose of efruxifermin showed a clinically meaningful reduction in liver fibrosis, or scarring, without other symptoms of MASH getting worse, compared to 15% of participants randomized to a placebo.
Patients with cirrhosis due to MASH have a severe form of the disease with few treatment options outside of a liver transplant. Once MASH progresses to cirrhosis, median survival is about five years, three times shorter than for patients with moderate, or mid-stage, MASH.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in